Simulations Plus (FRA:SD3) Notes Receivable: €0.00 Mil (As of Feb. 2026)


FRA:SD3 Simulations Plus Inc FRA:SD3
67 GF Score
Price €15.80
GF Value €32.93
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Simulations Plus Notes Receivable?

Simulations Plus FRA:SD3 67 Notes Receivable is €0.00 Mil as of Feb. 2026. GuruFocus rates FRA:SD3 with a GF Score™ of 67/100 and a GF Value™ of €32.93 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Simulations Plus's Notes Receivable for the quarter that ended in Feb. 2026 was €0.00 Mil.

Simulations Plus Notes Receivable Related Terms

Simulations Plus Notes Receivable Historical Data

* Premium members only.

The historical data trend for Simulations Plus's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simulations Plus Notes Receivable Chart

Simulations Plus Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Simulations Plus Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:SD3
67GF Score
Simulations Plus Inc FRA:SD3
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simulations Plus Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Simulations Plus (FRA:SD3) has a Notes Receivable of €0.00 Mil as of Feb. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Simulations Plus and its competitors.
Is Simulations Plus' Notes Receivable too high?
Simulations Plus' current Notes Receivable is €0.00 Mil. Overall, Simulations Plus has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' Notes Receivable compare to TBRG and CARL?
Simulations Plus' Notes Receivable of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Healthcare Providers & Services company?
A good Notes Receivable depends on the Healthcare Providers & Services industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Simulations Plus and its competitors. Simulations Plus's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (FRA:SD3) is currently considered Significantly Undervalued. The stock's GF Value™ is €32.93, compared to a current price of €15.80 — trading 52% below its estimated fair value. The current Notes Receivable is €0.00 Mil. Simulations Plus' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Simulations Plus (FRA:SD3), the current Notes Receivable is €0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simulations Plus (FRA:SD3) Overvalued in 2026?

Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued. The current stock price of €15.80 is trading 52% below its estimated GF Value™ of €32.93. GuruFocus considers Simulations Plus to be Significantly Undervalued.

Key valuation signals for FRA:SD3:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €32.93 vs. price of €15.80 (52% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the FRA:SD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simulations Plus Business Description

Other Exchanges SLP:USA
Address 800 Park Offices Drive, Suite 401, Research Triangle Park, Lancaster, NC, USA, 27709
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
67GF Score

Get the complete analysis for FRA:SD3

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.80
Price
€32.93
GF Value